Dyne Therapeutics (DYN) Income towards Parent Company (2019 - 2026)

Dyne Therapeutics (DYN) has 8 years of Income towards Parent Company data on file, last reported at -$165.9 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 28.92% year-over-year to -$165.9 million in Q1 2026; TTM through Mar 2026 was -$479.4 million, a 18.22% increase from a year earlier, with the FY2025 full-year figure at -$491.1 million, up 22.36% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$165.9 million, down from -$89.3 million in the prior quarter.
• Over the last five years, Income towards Parent Company for DYN reached as high as -$62.5 million in Q1 2022 and fell as low as -$250.1 million in Q2 2024.
• Historically, Income towards Parent Company has averaged -$123.7 million across 5 years, with a median of -$104.9 million in 2024.
• Across the five-year window, Income towards Parent Company sank 198.27% in 2022 and jumped 53.67% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$153.4 million in 2022, then sank by 42.66% to -$218.8 million in 2023, then soared by 53.12% to -$102.6 million in 2024, then rose by 12.92% to -$89.3 million in 2025, then sank by 85.77% to -$165.9 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$165.9 million in Q1 2026, -$89.3 million in Q4 2025, and -$108.3 million in Q3 2025.